Login to Your Account

Analyst: European Approval Unlikely

Dacogen Failure in MDS Phase III Offers Boost to Celgene's Vidaza

By Jennifer Boggs

Wednesday, July 2, 2008
Long-awaited survival data for Dacogen (decitabine) failed to show a significant survival advantage compared to best supportive care in patients with myelodysplastic syndromes, sending shares of SuperGen Inc. down 14.6 percent while giving a boost to Celgene Corp., which markets competing demethylation agent Vidaza. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription